Effects of pharmacists' intervention on anticoagulant management of patients treated with warfarin after heart valve replacement

doi:10.19803/j.1672-8629.2022.05.15

Abstract

Abstract: Objective To evaluate the effects of pharmaceutical care on patients chronically taking warfarin and highlight the importance of clinical pharmacists. Methods A total of 226 patients who had undergone heart valve replacement and took warfarin as an anticoagulation treatment between May 2018 and December 2019 were enrolled according to the inclusion criteria. These patients were followed up according to the pharmaceutical service process. Their knowledge of the anticoagulation treatment with warfarin and medication compliance after pharmacist interventions were compared, and the improvement of time in therapeutic range (TTR) was analyzed. Results After interventions by pharmacists, the patients' knowledge of the use of warfarin and medication compliance were improved significantly. The number of patients with good medication compliance increased from 19 (8.41%) to 121 (53.54%), and the TTR increased from 30.25% to 63.65% (P<; 0.05). Conclusion Pharmacists' intervention in patients under long-term anticoagulation treatment with warfarin can improve the efficacy and safety of this therapy.

Key words: heart valve replacement, warfarin, pharmacist intervention, anticoagulation, safety

CLC Number:

R96
R973.2

XIANG Yunxia, PU Wen, LI Dongfeng, WANG Jie. Effects of pharmacists' intervention on anticoagulant management of patients treated with warfarin after heart valve replacement[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 545-549.

References

[1] ROBERT R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a2020 update[J]. Pharmacol Res, 2020(152): 104609.
[2] CHEN M, CHEN XW, HONG XH, et al.Application of small molecule protein kinase inhibitors in tumor therapy[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2020, 47(10): 523-529.
[3] HABRE M, SALLOUM A, HABRE SB, et al.Skin adverse events in recently approved targeted therapies in solid malignancies[J]. Future Oncol, 2019, 15(3): 331-343.
[4] VAN SEBILLE YZ, GIBSON RJ, WARDILL HR, et al.Gastrointe-stinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer[J]. Curr Opin Support Palliat Care, 2016, 10(2): 152-156.
[5] DAMRONGWATANASUK R, Fradley MG.Cardiovascular complications of targeted therapies for chronic myeloid leukemia[J]. Curr Treat Options Cardiovasc Med, 2017, 19(4): 24.
[6] YANG H, WEI J, WANG JY, et al.Study on methods of adverse drug reaction/event reporting assessment[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(10): 581-584.
[7] National Medical Products Administration. Measures for the reporting and monitoring of adverse drug reaction(Decree No. 81 of the Ministry of Health) [EB/OL]. (2011-05-04) [2020-09-18]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325_7.html.
[8] ZHENG SR, SUN KX, ZHANG SW, et al.Report of cancer epidemiology in China, 2015[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2019, 41(1): 19-28.
[9] PAN F.Tumor molecular typing and targeted therapy are the frontiers of future research-interview with Professor Wu Yilong, Director of the National Lung Cancer Quality Control Center[J]. China Medical Herald(中国医药导报), 2019, 16(4): 1-3.
[10] MACDONALD JB, MACDONALD B, GOLITZ LE, et al.Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane[J]. J Am AcadDermatol, 2015, 72(2): 203-218.
[11] LI HY, YANG CP, JIN HT.Research progress of target related toxicity of anti-tumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 152-157.
[12] FIALA O, PESEK M, FINEK J, et al.Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice[J]. Neoplasma, 2013, 60(1): 26-32.
[13] XIE XD, GUO F. Further discussion on the research progress of cutaneous toxicities of anti-tumor molecular targeted drugs[C]. Proceedings of the 9th Chinese Symposium on Medical Oncology, the 4th Annual Meeting of Chinese Society for Clinical Oncologists,the2015 Annual Meeting of Clinical Cancer Chemotherapy Committee of China Anti Cancer Association(第九届中国肿瘤内科大会、第四届中国肿瘤医师大会、中国抗癌协会肿瘤临床化疗专业委员会2015年学术年会论文集). 2015.
[14] LIU S, KURZROCK R.Understanding toxicities of targeted agents: implications for anti-tumor activity and management[J]. Semin Oncol, 2015, 42(6): 863-875.
[15] SHAH DR, SHAH RR, MORGANROTH J.Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy[J]. Drug Saf, 2013, 36(6): 413-426.
[16] SHI Q, YANG X, REN L, et al.Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors[J]. Expert Opin Drug Metab Toxicol, 2020, 16(3): 217-226.
[17] FUNAKOSHI T, LATIF A, GALSKY MD.Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis[J]. Cancer Treat Rev, 2013, 39(7): 818-830.
[18] JIANG Q, CHEN SS, JIANG B, et al.Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients[J]. Journal of Peking University (Health Sciences) [北京大学学报(医学版)], 2003, 35(2): 136-140.
[19] PORTA C, COSMAI L, GALLIENI M, et al.Renal effects of targeted anticancer therapies[J]. Nat Rev Nephrol, 2015, 11(6): 354-370.
[20] HAYMAN SR, LEUNG N, GRANDE JP, et al.VEGF inhibition, hypertension, and renal toxicity[J]. Curr Oncol Rep, 2012, 14(4): 285-294.
[21] PORTA C, COSMAI L, GALLIENI M, et al.Renal effects of targeted anticancer therapies[J]. Nat Rev Nephrol, 2015, 11(6): 354-370.
[22] FAN QQ, ZHANG B, ZHAO B, et al.Advances in research on nephrotoxicity of small molecule kinase inhibitors[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2020, 29(3): 206-211.